Paid

Clinical Roundup

CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma

Early results from a chimeric antigen receptor T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional single-target approach helps minimizes treatment resistance, resulting in long-lasting remission for people with non-Hodgkin’s B-cell lymphoma that has come back or has not responded to treatment.